The artificial intelligence advantage: Supercharging exploratory data analysis.
Felix Conrad OettlJacob F OedingRobert FeldtChristophe LeyMichael Tobias HirschmannKristian Samuelssonnull nullPublished in: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA (2024)
Explorative data analysis (EDA) is a critical step in scientific projects, aiming to uncover valuable insights and patterns within data. Traditionally, EDA involves manual inspection, visualization, and various statistical methods. The advent of artificial intelligence (AI) and machine learning (ML) has the potential to improve EDA, offering more sophisticated approaches that enhance its efficacy. This review explores how AI and ML algorithms can improve feature engineering and selection during EDA, leading to more robust predictive models and data-driven decisions. Tree-based models, regularized regression, and clustering algorithms were identified as key techniques. These methods automate feature importance ranking, handle complex interactions, perform feature selection, reveal hidden groupings, and detect anomalies. Real-world applications include risk prediction in total hip arthroplasty and subgroup identification in scoliosis patients. Recent advances in explainable AI and EDA automation show potential for further improvement. The integration of AI and ML into EDA accelerates tasks and uncovers sophisticated insights. However, effective utilization requires a deep understanding of the algorithms, their assumptions, and limitations, along with domain knowledge for proper interpretation. As data continues to grow, AI will play an increasingly pivotal role in EDA when combined with human expertise, driving more informed, data-driven decision-making across various scientific domains. Level of Evidence: Level V - Expert opinion.
Keyphrases
- artificial intelligence
- machine learning
- data analysis
- big data
- deep learning
- decision making
- total hip arthroplasty
- endothelial cells
- end stage renal disease
- healthcare
- single cell
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- gene expression
- clinical trial
- dna methylation
- genome wide
- risk assessment
- patient reported outcomes
- rna seq
- clinical practice
- human health
- open label